DEA Bans Five Weird Hallucinogens: Tryptamine Trip Ends
Published Date: 9/23/2026
Proposed Rule
Summary
The Drug Enforcement Administration wants to put five specific hallucinogenic drugs into Schedule I, meaning they’ll be treated as illegal with strict rules. This affects anyone who makes, sells, studies, or owns these drugs, adding serious legal consequences. You have until October 23, 2026, to share your thoughts or ask for a hearing before the rule might become official.
Analyzed Economic Effects
6 provisions identified: 0 benefits, 5 costs, 1 mixed.
Five tryptamines moved to Schedule I
The Drug Enforcement Administration proposes to place 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT into Schedule I. If finalized, these substances would be treated as illegal under the Controlled Substances Act and subject to the civil, administrative, and criminal sanctions that apply to Schedule I drugs.
Retail sales banned; unauthorized possession illegal
The Controlled Substances Act does not allow retail sales of Schedule I drugs to the general public. Possession of any quantity of these substances without authorization under the CSA would be unlawful and could lead to prosecution.
DEA registration required to handle substances
Anyone who manufactures, distributes, imports, exports, researches, analyzes, or possesses these five tryptamines would need to be registered with DEA under the Controlled Substances Act. The rule says people currently handling them who are not registered must apply for registration and may not continue handling them unless DEA approves the application.
90-day rule to continue some research after scheduling
If the final rule is effectuated, a person already registered to conduct research with another Schedule I controlled substance may continue research on these five tryptamines only if they submit a completed application or modification to conduct research with them within 90 calendar days after the date the final rule takes effect. The person may continue research until they withdraw the application or the Administrator serves an order to show cause; if an order to show cause is served, a requested hearing must be held on an expedited basis not later than 45 calendar days after the request, unless the person agrees to a later date.
Surrender or transfer stock before effective date
People who are unwilling or unable to obtain a Schedule I registration must surrender or transfer all quantities of these substances to a DEA-registered person before the effective date of the final scheduling action, and dispose of them according to applicable law and 21 CFR part 1317. That means labs or suppliers holding stocks must either register or move/securely dispose of their inventories before the rule takes effect.
Schedule I security and storage rules apply
If these tryptamines are placed in Schedule I, they would be subject to Schedule I security requirements and must be handled and stored in accordance with the Controlled Substances Act and implementing regulations. That will require entities that keep these substances to meet Schedule I physical security and recordkeeping rules.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-19232, Esther Villanueva Valdes, M.D.; Decision and Order
Dr. Esther Villanueva Valdes from Puerto Rico lost her DEA registration because she’s no longer allowed to handle controlled substances and was excluded from federal health programs like Medicare and Medicaid. She didn’t ask for a hearing, so the decision to revoke her registration is final. This means she can’t legally prescribe or manage controlled drugs anymore, effective immediately.
2026-19231, Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
Starting October 21, 2026, diphenidine and its related forms will be officially listed as Schedule I drugs, meaning they’re considered highly controlled with no accepted medical use. This change affects anyone who makes, sells, studies, or even possesses diphenidine, bringing strict rules and serious penalties. The move helps the U.S. follow international drug laws and keep communities safer.
2026-18604, Joseph John Stubbers III, D.O.; Decision and Order
Dr. Joseph John Stubbers III from Ohio lost his DEA registration to handle controlled substances because he no longer has the legal authority to prescribe them in Ohio. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of February 28, 2026. This means he can’t legally prescribe or manage controlled drugs anymore, impacting his medical practice and patients.
2026-18597, Craig Cohen, DPM; Decision and Order
Dr. Craig Cohen from Ohio lost his DEA registration because he no longer has permission to handle controlled substances in his state. He didn’t respond to the DEA’s attempts to contact him or request a hearing, so the agency revoked his certificate. This means he can’t legally prescribe or manage controlled drugs anymore, effective immediately.
Previous / Next Documents
Previous: 2026-19370, Part 572; Anthropomorphic Test Devices; Test Device for Human Occupant Restraint 50th Percentile Adult Male Dummy (THOR-50M)
NHTSA is updating crash test rules to include a smarter crash test dummy called the THOR-50M, which better represents an average adult male. They’re asking for feedback on new spine designs and face foam options to make tests more accurate. If you’re involved in car safety or testing, get your comments in by October 22, 2026—this could shape future safety rules and testing costs.
Next: 2026-19411, Airworthiness Directives; Textron Aviation, Inc. (Type Certificate Previously Held by Cessna Aircraft Company) Airplanes
If you own or fly certain Textron (formerly Cessna) Model 402C and 414A airplanes, the FAA wants you to check your engine beams more often for cracks and replace them once they hit a new life limit. This keeps your plane safe and sound, but it means some extra inspections and possible replacements soon. Comments on this plan are open until November 9, 2026, so speak up if you have thoughts!